|
Ocular Therapeutix, Inc. (OCUL) DCF Avaliação |
Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
Design Profissional: Modelos Confiáveis E Padrão Da Indústria
Pré-Construídos Para Uso Rápido E Eficiente
Compatível com MAC/PC, totalmente desbloqueado
Não É Necessária Experiência; Fácil De Seguir
Ocular Therapeutix, Inc. (OCUL) Bundle
Avalie as perspectivas financeiras da Ocular Therapeutix, Inc. (OCUL) como um profissional! Esta calculadora DCF (OCUL) fornece finanças pré-preenchidas e flexibilidade para modificar o crescimento da receita, o WACC, as margens e outras suposições cruciais para se alinhar com suas projeções.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.4 | 43.5 | 51.5 | 58.4 | 63.7 | 86.2 | 116.5 | 157.5 | 213.0 | 288.0 |
| Revenue Growth, % | 0 | 150.08 | 18.32 | 13.49 | 9.03 | 35.21 | 35.21 | 35.21 | 35.21 | 35.21 |
| EBITDA | -146.1 | -75.6 | -61.9 | -66.4 | -176.1 | -86.2 | -116.5 | -157.5 | -213.0 | -288.0 |
| EBITDA, % | -839.48 | -173.74 | -120.22 | -113.64 | -276.42 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 2.8 | 2.4 | 2.1 | 3.0 | 3.8 | 6.3 | 8.5 | 11.5 | 15.6 | 21.1 |
| Depreciation, % | 15.93 | 5.56 | 4.1 | 5.1 | 5.94 | 7.33 | 7.33 | 7.33 | 7.33 | 7.33 |
| EBIT | -148.9 | -78.0 | -64.0 | -69.4 | -179.9 | -86.2 | -116.5 | -157.5 | -213.0 | -288.0 |
| EBIT, % | -855.42 | -179.3 | -124.32 | -118.74 | -282.36 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 228.1 | 164.2 | 102.3 | 195.8 | 392.1 | 86.2 | 116.5 | 157.5 | 213.0 | 288.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 12.3 | 21.1 | 21.3 | 26.2 | 32.4 | 44.1 | 59.6 | 80.6 | 109.0 | 147.4 |
| Account Receivables, % | 70.4 | 48.56 | 41.41 | 44.79 | 50.83 | 51.2 | 51.2 | 51.2 | 51.2 | 51.2 |
| Inventories | 1.2 | 1.3 | 2.0 | 2.3 | 3.0 | 3.8 | 5.2 | 7.0 | 9.5 | 12.9 |
| Inventories, % | 6.9 | 2.87 | 3.83 | 3.94 | 4.77 | 4.46 | 4.46 | 4.46 | 4.46 | 4.46 |
| Accounts Payable | 2.7 | 4.6 | 5.1 | 4.4 | 4.2 | 8.6 | 11.7 | 15.8 | 21.4 | 28.9 |
| Accounts Payable, % | 15.57 | 10.55 | 9.95 | 7.51 | 6.55 | 10.03 | 10.03 | 10.03 | 10.03 | 10.03 |
| Capital Expenditure | -.8 | -1.2 | -3.7 | -6.1 | -1.3 | -4.7 | -6.3 | -8.6 | -11.6 | -15.7 |
| Capital Expenditure, % | -4.83 | -2.74 | -7.21 | -10.42 | -2.02 | -5.45 | -5.45 | -5.45 | -5.45 | -5.45 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -152.7 | -128.7 | -57.2 | -69.4 | -179.9 | -84.3 | -114.0 | -154.1 | -208.4 | -281.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -161.5 | -134.5 | -59.1 | -78.4 | -184.6 | -90.8 | -125.7 | -169.9 | -229.7 | -310.6 |
| WACC, % | 11.59 | 11.59 | 11.47 | 11.59 | 11.59 | 11.57 | 11.57 | 11.57 | 11.57 | 11.57 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -632.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -317 | |||||||||
| Terminal Value | -3,311 | |||||||||
| Present Terminal Value | -1,915 | |||||||||
| Enterprise Value | -2,548 | |||||||||
| Net Debt | -316 | |||||||||
| Equity Value | -2,231 | |||||||||
| Diluted Shares Outstanding, MM | 158 | |||||||||
| Equity Value Per Share | -14.10 |
What You Will Get
- Real OCUL Financial Data: Pre-filled with Ocular Therapeutix’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Ocular Therapeutix’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Customizable Financial Metrics: Adjust essential parameters such as revenue projections, gross margin %, and R&D expenditures.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and other financial metrics with ease.
- High-Precision Accuracy: Leverages Ocular Therapeutix's actual financial data for reliable valuation results.
- Effortless Scenario Analysis: Evaluate various assumptions and analyze results without hassle.
- Efficiency Booster: Avoid the complexities of constructing detailed valuation models from the ground up.
How It Works
- Download the Template: Gain immediate access to the Excel-based OCUL DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Ocular Therapeutix’s intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential valuation shifts.
- Analyze and Decide: Utilize the outcomes to inform your investment or financial strategy.
Why Choose This Calculator for Ocular Therapeutix, Inc. (OCUL)?
- Designed for Industry Experts: A sophisticated tool utilized by healthcare analysts, investment managers, and researchers.
- Comprehensive Data: Ocular Therapeutix’s historical and projected financials are preloaded for precision.
- Versatile Scenario Analysis: Effortlessly model various forecasts and assumptions.
- Clear and Concise Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly Interface: Step-by-step guidance simplifies the entire calculation process.
Who Should Use Ocular Therapeutix, Inc. (OCUL)?
- Investors: Gain insights into innovative therapies and make informed investment choices.
- Healthcare Analysts: Utilize comprehensive data to assess the company's market position and growth potential.
- Consultants: Tailor presentations and reports for clients focusing on the ophthalmic pharmaceutical sector.
- Biotech Enthusiasts: Enhance your knowledge of drug development processes and therapeutic innovations.
- Educators and Students: Employ real-world case studies in academic settings related to biotechnology and pharmaceuticals.
What the Template Contains
- Pre-Filled Data: Contains Ocular Therapeutix’s historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model with automated calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC using custom inputs.
- Key Financial Ratios: Evaluate Ocular Therapeutix's profitability, efficiency, and leverage.
- Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
- Clear Dashboard: Visuals and tables summarizing essential valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.